Repurposing Valsartan May Protect Against Pulmonary Hypertension
Conditions: Pulmonary Arterial Hypertension; Right Heart Failure; Right Ventricular Dysfunction; Pulmonary Vascular Disorder Interventions: Drug: Valsartan 40 mg; Drug: Placebo Sponsors: University of Washington; National Heart, Lung, and Blood Institute (NHLBI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 25, 2023 Category: Research Source Type: clinical trials
Sacubitril-Valsartan in Heart Failure With Preserved Ejection Fraction and Secondary Mitral Valve Regurgitation
Conditions: Heart Failure With Preserved Ejection Fraction; Functional Mitral Regurgitation Interventions: Drug: Sacubitril-valsartan; Drug: Standard of care Sponsors: Ziekenhuis Oost-Limburg; Jessa Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 14, 2023 Category: Research Source Type: clinical trials
Initiation of ARNi and SGLT2i in Patients With HFrEF
Condition: Heart Failure With Reduced Ejection Fraction Interventions: Drug: Sacubitril-valsartan; Drug: SGLT2 inhibitor Sponsor: Universidade do Porto Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 14, 2023 Category: Research Source Type: clinical trials
Sacubitril-Valsartan in Heart Failure With Preserved Ejection Fraction and Secondary Mitral Valve Regurgitation
Conditions: Heart Failure With Preserved Ejection Fraction; Functional Mitral Regurgitation Interventions: Drug: Sacubitril-valsartan; Drug: Standard of care Sponsors: Ziekenhuis Oost-Limburg; Jessa Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 14, 2023 Category: Research Source Type: clinical trials
Initiation of ARNi and SGLT2i in Patients With HFrEF
Condition: Heart Failure With Reduced Ejection Fraction Interventions: Drug: Sacubitril-valsartan; Drug: SGLT2 inhibitor Sponsor: Universidade do Porto Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 14, 2023 Category: Research Source Type: clinical trials
Sacubitril-Valsartan in Heart Failure With Preserved Ejection Fraction and Secondary Mitral Valve Regurgitation
Conditions: Heart Failure With Preserved Ejection Fraction; Functional Mitral Regurgitation Interventions: Drug: Sacubitril-valsartan; Drug: Standard of care Sponsors: Ziekenhuis Oost-Limburg; Jessa Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 14, 2023 Category: Research Source Type: clinical trials
Initiation of ARNi and SGLT2i in Patients With HFrEF
Condition: Heart Failure With Reduced Ejection Fraction Interventions: Drug: Sacubitril-valsartan; Drug: SGLT2 inhibitor Sponsor: Universidade do Porto Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 14, 2023 Category: Research Source Type: clinical trials
Sacubitril-Valsartan in Heart Failure With Preserved Ejection Fraction and Secondary Mitral Valve Regurgitation
Conditions: Heart Failure With Preserved Ejection Fraction; Functional Mitral Regurgitation Interventions: Drug: Sacubitril-valsartan; Drug: Standard of care Sponsors: Ziekenhuis Oost-Limburg; Jessa Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 14, 2023 Category: Research Source Type: clinical trials
Initiation of ARNi and SGLT2i in Patients With HFrEF
Condition: Heart Failure With Reduced Ejection Fraction Interventions: Drug: Sacubitril-valsartan; Drug: SGLT2 inhibitor Sponsor: Universidade do Porto Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 14, 2023 Category: Research Source Type: clinical trials
Sacubitril-Valsartan in Heart Failure With Preserved Ejection Fraction and Secondary Mitral Valve Regurgitation
Conditions: Heart Failure With Preserved Ejection Fraction; Functional Mitral Regurgitation Interventions: Drug: Sacubitril-valsartan; Drug: Standard of care Sponsors: Ziekenhuis Oost-Limburg; Jessa Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 14, 2023 Category: Research Source Type: clinical trials
Initiation of ARNi and SGLT2i in Patients With HFrEF
Condition: Heart Failure With Reduced Ejection Fraction Interventions: Drug: Sacubitril-valsartan; Drug: SGLT2 inhibitor Sponsor: Universidade do Porto Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 14, 2023 Category: Research Source Type: clinical trials
